Nasdaq IPOs

IN8bio, a Phase 1 biotech developing allogeneic T cell therapies for cancer and solid tumors, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The company's pipeline contains lead candidates INB-200, which is currently in a Phase 1 trial for

dMY Technology Group III, the third blank check company formed by Niccolo de Masi and Harry You targeting an app business, filed on Friday with the SEC to raise up to $250 million in an initial public offering. The Las Vegas, NV-based company plans to raise $250 million by offer

Opthea, an Australian Phase 3 biotech developing VEGF inhibitors for wet AMD, raised $128 million by offering 9.5 million ADS equivalents at $13.50, below the as-converted last close of its shares on the ASX (OPT). The ADS equivalents offered consisted of 8.6 million ADSs and pre

Opthea, an Australian Phase 3 biotech developing VEGF inhibitors for wet AMD, raised $128 million by offering 9.5 million ADS equivalents at $13.50, below the as-converted last close of its shares on the ASX (OPT). The ADS equivalents offered consisted of 8.6 million ADSs and pre

Gatos Silver, a US producer of silver and other precious metals, announced terms for its IPO on Friday. It plans to dual-list its shares on the NYSE and the Toronto Stock Exchange. The Greenwood Village, CO-based company plans to raise $150 million by offering 18.8 million

William Penn Bancorporation, a Pennsylvania -based bank with twelve full-service branches, filed to list on the Nasdaq in a subscription offering on Thursday.  Note: Renaissance Capital will not track William Penn Bancorporation's listing in our 2020 IPO stat

Kiromic BioPharma, a preclinical biotech developing immunotherapies for blood cancers and solid tumors, raised $15 million by offering 1.3 million shares at $12, the low end of the range of $12 to $14. Kiromic BioPharma plans to list on the Nasdaq under the symbol KRBP. ThinkEqu

Bridgetown Holdings, a blank check company formed by Pacific Century and Thiel Capital targeting "new economy" sectors in Southeast Asia, raised $550 million by offering 55 million units at $10. The company originally planned to offer 50 million units before increasing the unit o

Aligos Therapeutics, a Phase 1 biotech developing oligonucleotide therapies for viral and liver diseases, raised $150 million by offering 10 million shares at $15, within the range of $14 to $16.  Aligos Therapeutics plans to list on the Nasdaq under the symbol ALGS. J.P. M

Tarsus Pharmaceuticals, a Phase 3 biotech developing therapies for ophthalmic conditions, raised $88 million by offering 5.5 million shares at $16, within the range of $15 to $17. The company offered 0.5 million more shares than anticipated. At pricing, the company raised 10% mor

Praxis Precision Medicines, a Phase 2 biotech developing therapies for CNS disorders using genetic insights, raised $190 million by offering 10 million shares at $19, above the range of $17 to $18.  The company originally filed to offer 7.4 million shares at a range of $16

Eargo, which makes discreet and rechargeable hearing aid systems, raised $141 million by offering 7.9 million shares at $18, above the range of $14 to $16. The company originally filed to offer 6.7 million shares. Eargo plans to list on the Nasdaq under the symbol EAR. J.P. Morg

L&F Acquisition, the second blank check company formed by Victory Park Capital targeting the GRCL sectors, filed on Thursday with the SEC to raise up to $200 million in an initial public offering. The Chicago, IL-based company plans to raise $200 million by offering 20 milli

Turmeric Acquisition, a blank check company formed by MPM Capital targeting the biotech industry, raised $85 million by offering 8.5 million units at $10. The company originally planned to offer 10 million units before decreasing the unit offering on Tuesday. Each unit con

Spartacus Acquisition, a blank check company targeting a TMT business, raised $200 million by offering 20 million units at $10. The company offered 5 million fewer units than anticipated. Each unit consists of one share of common stock and one-half of a warrant, exercisable

H.I.G. Acquisition, a blank check company formed by H.I.G. Capital, lowered the proposed deal size for its upcoming IPO on Thursday. The Miami, FL-based company now plans to raise $325 million by offering 32.5 million units at a price of $10. The company had previously filed to

Eastern Bankshares, a Massachusetts bank with 89 branches in eastern Massachusetts and New Hampshire, raised $1.8 billion through a best-efforts subscription offering in connection with its conversion from a mutual holding company to a publicly-traded stock corporation. Eastern B

Eastern Bankshares, a Massachusetts bank with 89 branches in eastern Massachusetts and New Hampshire, raised $1.8 billion in a best-efforts subscription offering on Thursday, offering 179.3 million shares of common stock at $10. The company donated an additional 7.5 million share

Guild Holdings, which provides personalized mortgage services and loan origination, announced terms for its IPO on Thursday. The San Diego, CA-based company plans to raise $153 million by offering 8.5 million shares (100% insider) at a price range of $17 to $19. At the midpoint

Motion Acquisition, a blank check company formed by the former CEO of Fleetmatics targeting the telematics industry, raised $115 million by offering 11.5 million units at $10. The company offered 1.5 million fewer units than anticipated. Each unit consists of one share of co